Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.91)
# 1,632
Out of 4,983 analysts
73
Total ratings
38.96%
Success rate
1.77%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Buy | $9 → $11 | $5.44 | +102.21% | 4 | Sep 2, 2025 | |
| VALN Valneva SE | Reiterates: Buy | $18 | $9.99 | +80.18% | 2 | Aug 25, 2025 | |
| DERM Journey Medical | Initiates: Buy | $13 | $7.20 | +80.56% | 2 | Aug 25, 2025 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.07 | +291.52% | 2 | Aug 21, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $5.25 | +128.57% | 3 | Aug 20, 2025 | |
| GNFT Genfit | Assumes: Buy | $9 | $4.17 | +115.89% | 1 | Aug 19, 2025 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $3.40 | +282.35% | 4 | Aug 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $7 | $1.62 | +331.30% | 2 | Aug 13, 2025 | |
| XERS Xeris Biopharma Holdings | Assumes: Buy | $10 | $7.59 | +31.76% | 1 | Aug 12, 2025 | |
| COLL Collegium Pharmaceutical | Assumes: Buy | $44 | $36.07 | +21.99% | 6 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $93 | $97.26 | -4.38% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $11.71 | +45.18% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $6.26 | +363.26% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $23.13 | +21.05% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.66 | +161.10% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.43 | +249.93% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.24 | +385.83% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $1.99 | +151.89% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.07 | +745.07% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.13 | +158.30% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.61 | +211.53% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.13 | +118.18% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.35 | +2,202.82% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $7.85 | +103.82% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.50 | +1,916.54% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $23.83 | +1,809.36% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $35.08 | +68.19% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $128.23 | +40.37% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $3.59 | +6,028.13% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $27.79 | +15.15% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.69 | +1,301,675.15% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $14.63 | +241.76% | 1 | Jul 12, 2018 |
MannKind
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $11
Current: $5.44
Upside: +102.21%
Valneva SE
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $9.99
Upside: +80.18%
Journey Medical
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.20
Upside: +80.56%
Achieve Life Sciences
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $3.07
Upside: +291.52%
Eupraxia Pharmaceuticals
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $5.25
Upside: +128.57%
Genfit
Aug 19, 2025
Assumes: Buy
Price Target: $9
Current: $4.17
Upside: +115.89%
PolyPid
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.40
Upside: +282.35%
Connect Biopharma Holdings
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $1.62
Upside: +331.30%
Xeris Biopharma Holdings
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $7.59
Upside: +31.76%
Collegium Pharmaceutical
Aug 11, 2025
Assumes: Buy
Price Target: $44
Current: $36.07
Upside: +21.99%
Aug 8, 2025
Maintains: Buy
Price Target: $84 → $93
Current: $97.26
Upside: -4.38%
Aug 8, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $11.71
Upside: +45.18%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $6.26
Upside: +363.26%
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $23.13
Upside: +21.05%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $7.66
Upside: +161.10%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $7.43
Upside: +249.93%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.24
Upside: +385.83%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.99
Upside: +151.89%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.07
Upside: +745.07%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $8.13
Upside: +158.30%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.61
Upside: +211.53%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $4.13
Upside: +118.18%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.35
Upside: +2,202.82%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $7.85
Upside: +103.82%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.50
Upside: +1,916.54%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $23.83
Upside: +1,809.36%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $35.08
Upside: +68.19%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $128.23
Upside: +40.37%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $3.59
Upside: +6,028.13%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $27.79
Upside: +15.15%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.69
Upside: +1,301,675.15%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $14.63
Upside: +241.76%